Browse by People

Collapse authors list.
Kudo, Masatoshi ORCID: 0000-0002-4102-3474, Finn, Richard S ORCID: 0000-0003-2494-2126, Qin, Shukui, Han, Kwang-Hyub, Ikeda, Kenji, Cheng, Ann-Lii ORCID: 0000-0002-9152-6512, Vogel, Arndt ORCID: 0000-0003-0560-5538, Tovoli, Francesco ORCID: 0000-0002-8350-1155, Ueshima, Kazuomi ORCID: 0000-0002-7577-5789, Aikata, Hiroshi ORCID: 0000-0002-3409-2156 et al (show 10 more authors) , López, Carlos López, Pracht, Marc, Meng, Zhiqiang, Daniele, Bruno, Park, Joong-Won, Palmer, Daniel ORCID: 0000-0002-7147-5703, Tamai, Toshiyuki, Saito, Kenichi, Dutcus, Corina E and Lencioni, Riccardo (2023) Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study. Journal of hepatology, 78 (1). pp. 133-141.

Collapse authors list.
Verset, Gontran, Borbath, Ivan, Karwal, Mark, Verslype, Chris, Van Vlierberghe, Hans, Kardosh, Adel, Zagonel, Vittorina, Stal, Per, Sarker, Debashis, Palmer, Daniel H ORCID: 0000-0002-7147-5703 et al (show 16 more authors) , Vogel, Arndt, Edeline, Julien, Cattan, Stephane, Kudo, Masatoshi, Cheng, Ann-Lii, Ogasawara, Sadahisa, Daniele, Bruno, Chan, Stephen L, Knox, Jennifer J, Qin, Shukui, Siegel, Abby B, Chisamore, Michael, Hatogai, Ken, Wang, Anran, Finn, Richard S and Zhu, Andrew X (2022) Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. CLINICAL CANCER RESEARCH, 28 (12). pp. 2547-2554.

Collapse authors list.
Kudo, Masatoshi, Finn, Richard S, Edeline, Julien, Cattan, Stephane, Ogasawara, Sadahisa, Palmer, Daniel H ORCID: 0000-0002-7147-5703, Verslype, Chris, Zagonel, Vittorina, Fartoux, Laetitia, Vogel, Arndt et al (show 11 more authors) , Sarker, Debashis, Verset, Gontran, Chan, Stephen L, Knox, Jennifer, Daniele, Bruno, Yau, Thomas, Gurary, Ellen B, Siegel, Abby B, Wang, Anran, Cheng, Ann-Lii and Zhu, Andrew X (2022) Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. EUROPEAN JOURNAL OF CANCER, 167. pp. 1-12.

Meyer, Tim, Palmer, Daniel H ORCID: 0000-0002-7147-5703, Cheng, Ann-Lii, Hocke, Julia, Loembe, Arsene-Bienvenu and Yen, Chia-Jui (2017) mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib. LIVER INTERNATIONAL, 37 (07). pp. 1047-1055.